The Cambridge BRC already has strong links with industry. Jointly funded projects include those below.
Office for Translational Research
BRC provides core-funding for the Office for Translational Research (OTR) which supports researchers from the Cambridge University Health Partners (CUHP) Partner who would like to translate their basic biological, biomedical or clinical research findings into practical human health applications, such as:
- new therapeutics
- medical devices
- other human health interventions
The OTR provides practical support in three major areas:
- Translational Research Project development and management
- Industry/academia research collaboration development
- Events, secondments and training to enable cross-sector (private, academic, NHS) knowledge exchange
Industry/academia Collaboration Opportunities
The OTR is currently managing a number of Cambridge-specific Industry Collaboration Initiatives, many of which are co-funded by the BRC. Some examples are listed below, but for more information please see our Academia/ Industry collaborations pages.
GSK /Cambridge Strategic Alliance
The GSK/Cambridge Strategic Alliance established between GSK, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust builds on collaborations between the partners that bring together a variety of unique and complementary expertise and capabilities, from basic biology through to clinical studies. The alliance has a long term ambition to jointly deliver new medicine to patients in the next 5-10 years. Via the Varsity Funding programme it currently supports a portfolio of collaborative GSK/Cambridge projects.
For more information about Cambridge/ GSK collaboration opportunities read here.
Experimental Medicine Training Initiative (EMI) with AZ/MedImmune and GSK
The Experimental Medicine Training Initiative (EMI) is an exciting, new strategic scheme, supported by the University of Cambridge in partnership with Cambridge University Hospitals, NIHR Cambridge Biomedical Research Centre and Industry Partners AstraZeneca/MedImmune and GSK. It provides high quality training for highly motivated, bright and enthusiastic clinical and non-clinical scientists in the design and execution of Experimental Medicine studies, equipping them with the knowledge and skills to lead Experimental Medicine studies in the future. The initiative will also recruit experienced individuals to new, joint posts, created as part of the initiative, to support Experimental Medicine studies and training in Cambridge, and create opportunities for the exchange of individuals between partners through sabbaticals and secondments.
Further information about the initiative can be found here.
Cambridge MedImmune PhD Programme in Biomedical Research
This innovative 4 year programme – co-funded by the BRC - focuses on topical areas of biomedical research falling within the scope of interest of both the University of Cambridge and MedImmune. The programme provides students with the opportunity to work at the interface of academia and industry and aims to promote pre-clinical research, provide access to innovative translational research and to strengthen understanding of disease.
More information about the programme can be found here.
EMINENT – Experimental Medicine Initiative to Explore New Therapies
Initiative between the MRC, GSK and the Universities of Cambridge, Glasgow, Newcastle, Imperial College and UCL
Cambridge was part of a successful £16 million bid to work with the MRC, GSK and four other UK universities to improve scientists’ understanding of inflammatory and fibrotic diseases using experimental medicine approaches. The successful bid was led by Professor Edwin Chilvers (Medicine) and co-ordinated by the OTR. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network brings together teams of researchers from Universities of Cambridge, Glasgow, Newcastle, Imperial College and UCL with GSK researchers. It is hoped that combining the disease biology expertise of the academics with GSK’s drug development programme will lead to breakthroughs that will accelerate the development of novel treatments. MRC funding of £8m over five years will support academic costs of the EMINENT network, with a similar contribution from GSK. The aim is to support up to ten experimental medicine projects over five years.
For more information about EMINENT please contact the OTR.
GSK Clinical Unit Cambridge
Cambridge BRC have been fortunate to collaborate with industry in an innovative and productive manner since 1999 with the co-location of GlaxoSmithKline's Clinical Unit Cambridge on the BRC site. This Phase 1/2 unit allows the BRC to perform unique translational studies in healthy volunteers and patients, thereby highlighting the benefits of close interaction between the academic community and industry in bringing new drugs for patient benefit.
A new PET/CT scanning department ' one of only a handful in the UK, and the first in East Anglia ' opened in December 2008.
The department is the result of a collaboration between the Cambridge Biomedical Research Centre, Merck Sharp & Dohme (MSD), Cancer Research UK, Addenbrooke's and the University of Cambridge.
NIHR BRC & GSK linked Translational Medicine Research Fellowships
Several Trust Fellowships posts are joint funded by GSK.
This ground-breaking new concept will tap into the highest quality thinking in academia to optimise the early clinical development of new GlaxoSmithKline medicines in a model of shared risk and reward.
If your company is interested in collaborating with the Cambridge BRC please see the contact pages for the individual themes.